Kalvista Pharmaceuticals Inc (KALV)

May 25, 2026

Why (KALV) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 25, 2026

May 21, 2026

Frazier Life Sciences funds (NASDAQ: KALV) disclose updated KalVista ownership - Stock Titan

May 21, 2026

May 19, 2026

Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? - TradingView

May 19, 2026

May 19, 2026

KalVista (KALV) CEO nets RSU shares after tax-related stock sale - Stock Titan

May 19, 2026

May 19, 2026

KalVista (KALV) CDO sells shares to cover RSU tax obligations - Stock Titan

May 19, 2026

May 19, 2026

KalVista Pharmaceuticals (KALV) CMO covers RSU taxes with 1,032-share sale - Stock Titan

May 19, 2026

May 19, 2026

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc.KALV - Business Wire

May 19, 2026

May 18, 2026

KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47 - MSN

May 18, 2026

May 17, 2026

The $1.9 Billion Bet: Chiesi Acquires KalVista, Redefining Rare Disease Value - Kavout

May 17, 2026

May 16, 2026

Assessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum - simplywall.st

May 16, 2026

May 16, 2026

Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks - TipRanks

May 16, 2026

May 15, 2026

Point72 entities report 4.2% stake in KalVista (NASDAQ: KALV) — 2.14M shares - Stock Titan

May 15, 2026

May 14, 2026

Brodsky & Smith investigates fiduciary duty breaches in mergers of KalVista, Thermon, Sila, and Lisata. - Pluang

May 14, 2026

May 14, 2026

KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN

May 14, 2026

May 14, 2026

Chiesi to acquire KalVista (NASDAQ: KALV) in $27 per share cash deal - Stock Titan

May 14, 2026

May 14, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 14, 2026

May 14, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA) - GlobeNewswire Inc.

May 14, 2026

May 14, 2026

KalVista to offer $110M in convertible notes; shares down 10% - MSN

May 14, 2026

May 14, 2026

Understanding Momentum Shifts in (KALV) - Stock Traders Daily

May 14, 2026

May 13, 2026

KalVista CEO Benjamin Palleiko sells $88,730 in company stock By Investing.com - Investing.com India

May 13, 2026

May 13, 2026

Kalvista Pharmaceuticals stock hits 52-week high at $26.85 By Investing.com - Investing.com Nigeria

May 13, 2026

May 13, 2026

KalVista CEO Benjamin Palleiko sells $88,730 in company stock - Investing.com

May 13, 2026

May 13, 2026

KalVista (NASDAQ: KALV) board backs $27 cash tender offer and planned merger - Stock Titan

May 13, 2026

May 13, 2026

SilverArc (KALV) files 2.88M-share Schedule 13G stake disclosure - Stock Titan

May 13, 2026

May 13, 2026

KalVista (KALV) CEO Palleiko sells shares to cover taxes after RSU vesting - Stock Titan

May 13, 2026

May 13, 2026

Kalvista Pharmaceuticals stock hits 52-week high at $26.85 - Investing.com

May 13, 2026

May 13, 2026

Chiesi (NASDAQ: KALV) offers $27.00 per share to acquire KalVista - Stock Titan

May 13, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 10, 2026

Citizens Maintains KalVista Pharmaceuticals (KALV) Market Outperform Recommendation - MSN

May 10, 2026

May 10, 2026

F m Investments LLC Purchases 37,486 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat

May 10, 2026

May 09, 2026

A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance

May 09, 2026

May 08, 2026

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - AOL.com

May 08, 2026

May 08, 2026

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

May 08, 2026

May 08, 2026

Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Hold Rating, Maintains Target Price $27 - Moomoo

May 08, 2026

May 08, 2026

Chiesi Continues Hunt For Rare Disease Drugs After KalVista Acquisition - Citeline News & Insights

May 08, 2026

May 08, 2026

Press Release Distribution India - Business Wire India

May 08, 2026

May 07, 2026

Stifel Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo

May 07, 2026

May 07, 2026

Chiesi to buy Kalvista, developer of HAE treatment Ekterly - Angioedema News

May 07, 2026

May 07, 2026

Kalvista Pharmaceuticals stock hits 52-week high at 26.77 USD By Investing.com - Investing.com Australia

May 07, 2026

May 06, 2026

Kalvista Pharmaceuticals stock hits 52-week high at 26.77 USD - Investing.com

May 06, 2026

May 05, 2026

Needham downgrades KalVista Pharmaceuticals (KALV) - MSN

May 05, 2026

May 05, 2026

Chiesi Farmaceutici (NASDAQ: KALV) offers $27.00 per share to buy KalVista - Stock Titan

May 05, 2026

May 05, 2026

KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal - MSN

May 05, 2026

May 04, 2026

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? - Sahm

May 04, 2026